Polina E Kisaretova1, Svetlana S Kirikovich1, Genrich S Ritter1,2, Yaroslav R Efremov1,2, Oleg S Taranov3, Tatyana D Dubatolova4, Anastasia S Proskurina1, Ekaterina A Potter1, Evgenia V Dolgova1, Sergey V Sidorov2,5, Aleksandr A Ostanin6, Elena R Chernykh6, Sergey S Bogachev7. 1. Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia. 2. Novosibirsk State University, Novosibirsk, Russia. 3. State Research Center of Virology and Biotechnology "VECTOR", Novosibirsk, Russia. 4. Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia. 5. Oncology Department of Municipal Hospital No 1, Novosibirsk, Russia. 6. Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia. 7. Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia labmolbiol@mail.ru.
Abstract
BACKGROUND/AIM: We previously have described the "3+1" tumors cure approach consisting of individual time schedule of cyclophosphamide and dsDNA preparation administrations. The aim of the study was to adapt the "3+1" approach based on eradication of cancer stem cells to the model of murine ascitic cyclophosphamide-resistant lymphosarcoma (RLS). MATERIALS AND METHODS: Adaptation of the "3+1" approach includes the identification of the timing to disrupt the tumorigenic potential of a certain tumor. RESULTS: The proposed therapeutic scheme allowed complete reduction of primary RLS ascites in experimental animals. However, reduction of primary ascites due to the complementary action of cyclophosphamide and dsDNA was inevitably followed by the development of a secondary one, most likely arising from a solid carcinomatous formation in the peritoneal wall. CONCLUSION: The "3+1" approach resulted in the elimination of cancer stem cells, and, as a consequence, in the complete reduction of RLS ascites. Copyright
BACKGROUND/AIM: We previously have described the "3+1" tumors cure approach consisting of individual time schedule of cyclophosphamide and dsDNA preparation administrations. The aim of the study was to adapt the "3+1" approach based on eradication of cancer stem cells to the model of murine ascitic cyclophosphamide-resistant lymphosarcoma (RLS). MATERIALS AND METHODS: Adaptation of the "3+1" approach includes the identification of the timing to disrupt the tumorigenic potential of a certain tumor. RESULTS: The proposed therapeutic scheme allowed complete reduction of primary RLS ascites in experimental animals. However, reduction of primary ascites due to the complementary action of cyclophosphamide and dsDNA was inevitably followed by the development of a secondary one, most likely arising from a solid carcinomatous formation in the peritoneal wall. CONCLUSION: The "3+1" approach resulted in the elimination of cancer stem cells, and, as a consequence, in the complete reduction of RLS ascites. Copyright
Authors: Anastasia S Proskurina; Victoria V Kupina; Yaroslav R Efremov; Evgenia V Dolgova; Vera S Ruzanova; Genrikh S Ritter; Ekaterina A Potter; Svetlana S Kirikovich; Evgeniy V Levites; Alexandr A Ostanin; Elena R Chernykh; Oksana G Babaeva; Sergey V Sidorov; Sergey S Bogachev Journal: Breast Cancer (Auckl) Date: 2022-02-14
Authors: Evgeniya V Dolgova; Svetlana S Kirikovich; Evgeniy V Levites; Vera S Ruzanova; Anastasia S Proskurina; Genrikh S Ritter; Oleg S Taranov; Nikolay A Varaksin; Tatiana G Ryabicheva; Olga Yu Leplina; Alexandr A Ostanin; Elena R Chernykh; Sergey S Bogachev Journal: Int J Mol Sci Date: 2022-07-22 Impact factor: 6.208
Authors: Anastasia S Proskurina; Vera S Ruzanova; Alexandr A Ostanin; Elena R Chernykh; Sergey S Bogachev Journal: Transl Cancer Res Date: 2021-11 Impact factor: 1.241